News
-
-
COMMUNIQUÉ DE PRESSE
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Kineta reopens enrollment for VISTA-101 clinical trial with KVA12123 antibody. Positive results at AACR 2024. TuHURA and Kineta join forces. Acquisition pending. Kintara merger progresses -
-
-
COMMUNIQUÉ DE PRESSE
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
TuHURA Biosciences and Kintara Therapeutics announce an Exclusivity Agreement for potential acquisition of KVA12123 anti-VISTA antibody. KVA12123 aims to reverse VISTA immune suppression and enhance tumor immunity -
-
-
COMMUNIQUÉ DE PRESSE
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. provide overview of recent corporate and clinical advancements, with upcoming milestones including merger closing and clinical trial commencement -
-
